BenevolentAI gets late-stage compounds from Janssen
Executive Summary
Janssen Pharmaceutica NV licensed artificial intelligence firm BenevolentAI exclusive global rights to develop, manufacture, and commercialize a series of clinical-stage small-molecule drug candidates and related patents for all indications.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice